Mirum Pharmaceuticals to Participate in SVB Securities Global Biopharma Conference
-
Company presentation
Wednesday, February 15 , starting at5:00 p.m. ET
Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.
About
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC.
Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in two potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230209005304/en/
Investor Contacts:
investors@mirumpharma.com
ir@mirumpharma.com
Media Contact:
media@mirumpharma.com
Source: